BioCentury | Feb 26, 2020
Distillery Therapeutics

Boosting FGF21 signaling to treat pancreatitis

DISEASE CATEGORY: Gastrointestinal INDICATION: Pancreatitis FGF21 replacement therapy or inhibition of PERK-mediated FGF21 repression could treat pancreatitis. Pancreatic levels of FGF21 protein were lower in 52 patients with acute or chronic pancreatitis than in 14...
BioCentury | May 17, 2019
Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Innovations | Mar 15, 2019
Tools & Techniques

Synthetic solutions for immuno-oncology

Synthorx Inc. is poised to enter the clinic this year with an IL-2 therapy that could validate its synthetic DNA platform. Marrying its click chemistry and unnatural amino acid technology with pegylation, the company is...
BC Extra | Mar 12, 2019
Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
BC Week In Review | Mar 8, 2019
Company News

BeiGene, Ambrx partner to discover, develop cancer biologics

BeiGene partnered with Ambrx to discover cancer therapeutics using the latter's site-specific conjugation technology. The technology uses cell lines engineered with transfer RNAs (tRNAs)/tRNA synthase that can incorporate non-natural amino acids into specified peptide and...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Oct 26, 2018
Financial News

First close for China Everbright’s new healthcare fund

China Everbright Ltd. (HKSE:165) completed the first close of its third healthcare fund, raising more than RMB800 million ($115.4 million). The CEL Healthcare Fund III's target is RMB1.5 billion ($216.3 million). According to China Everbright,...
BC Extra | Oct 23, 2018
Financial News

First close for China Everbright’s new healthcare fund

China Everbright Ltd. (HKSE:165) completed the first close of its third healthcare fund, raising more than RMB800 million ($115.4 million). The CEL Healthcare Fund III's target size is RMB1.5 billion ($216.3 million). According to China...
BC Extra | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
Items per page:
1 - 10 of 110
BioCentury | Feb 26, 2020
Distillery Therapeutics

Boosting FGF21 signaling to treat pancreatitis

DISEASE CATEGORY: Gastrointestinal INDICATION: Pancreatitis FGF21 replacement therapy or inhibition of PERK-mediated FGF21 repression could treat pancreatitis. Pancreatic levels of FGF21 protein were lower in 52 patients with acute or chronic pancreatitis than in 14...
BioCentury | May 17, 2019
Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Innovations | Mar 15, 2019
Tools & Techniques

Synthetic solutions for immuno-oncology

Synthorx Inc. is poised to enter the clinic this year with an IL-2 therapy that could validate its synthetic DNA platform. Marrying its click chemistry and unnatural amino acid technology with pegylation, the company is...
BC Extra | Mar 12, 2019
Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
BC Week In Review | Mar 8, 2019
Company News

BeiGene, Ambrx partner to discover, develop cancer biologics

BeiGene partnered with Ambrx to discover cancer therapeutics using the latter's site-specific conjugation technology. The technology uses cell lines engineered with transfer RNAs (tRNAs)/tRNA synthase that can incorporate non-natural amino acids into specified peptide and...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Oct 26, 2018
Financial News

First close for China Everbright’s new healthcare fund

China Everbright Ltd. (HKSE:165) completed the first close of its third healthcare fund, raising more than RMB800 million ($115.4 million). The CEL Healthcare Fund III's target is RMB1.5 billion ($216.3 million). According to China Everbright,...
BC Extra | Oct 23, 2018
Financial News

First close for China Everbright’s new healthcare fund

China Everbright Ltd. (HKSE:165) completed the first close of its third healthcare fund, raising more than RMB800 million ($115.4 million). The CEL Healthcare Fund III's target size is RMB1.5 billion ($216.3 million). According to China...
BC Extra | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
Items per page:
1 - 10 of 110